Back to journals
Academic Journal

Cancer

3 Papers Indexed in Blossom

Published Papers

Paywallindividual

Long-term benefits of single-dose psilocybin in depressed patients with cancer

In a phase 2 trial of 30 cancer patients with major depressive disorder, a single 25 mg dose of psilocybin with psychological support produced robust antidepressant and anxiolytic effects maintained at two years. About 54% showed significant depression reduction (50% sustained) and roughly 46% showed significant anxiety reduction (43% sustained), suggesting a potentially paradigm‑changing alternative to traditional antidepressants.

Published
Journal
Cancer
Authors
Agrawal, M., Roddy, K., Jenkins, B., Leeks, C., Emanuel, |. E.
Paywallindividual

Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis

In interviews with 28 cancer patients with major depressive disorder, a combined model of psilocybin‑assisted simultaneous individual and group therapy was generally judged acceptable and was felt to enhance perceived safety, preparedness, connection and opportunities for self‑transcendence and compassion. Participants emphasised the therapeutic framework, the complementary value of individual sessions, and careful attention to group size and interaction structure as key factors influencing acceptability and scalability in cancer care.

Published
Journal
Cancer
Authors
Beaussant, Y., Tarbi, E., Nigam, K. B., Miner, S., Sager, Z., Sanders, J. J., Ljuslin, M., Thambi, P., Tulsky, J., Agrawal, M., Guérin, B.
Paywallindividual

Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder

In a phase 2 open‑label trial, a single 25 mg dose of psilocybin given in a group therapy setting with one‑to‑one therapist support was safe and feasible in 30 patients with cancer and major depressive disorder, with no psilocybin‑related serious adverse events. The treatment produced a large reduction in depressive symptoms (mean 19.1‑point decrease; 80% sustained response; 50% remission at week 1 maintained through 8 weeks), suggesting clinical efficacy warranting further study.

Published
Journal
Cancer
Authors
Agrawal, M., Richards, B. D., Richards, W. A., Beaussant, Y., Shnayder, S., Ameli, R., Roddy, K., Stevens, N., Schor, N., Honstein, H., Jenkins, B., Bates, M., Thambi, P.

Quick Facts

Papers Indexed
3
h-Index
349
Open Access
No
Publisher
Wiley
Country
United States
Website
Visit